ICER ‘s final evidence report on therapies for IgA nephropathy
US health technology assessor the Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of Otsuka (TYO:4578) sibeprenlimab (Voyxact) , Vera Therapeutics’ (Nasdaq: VERA) atacicept and delayed-release budesonide (Nefecon, Tarpeyo) from Calliditas Therapeutics (Nasdaq Stockholm: CALT) in IgA nephropathy.
“Even with greater recognition that IgA nephropathy often progresses to end-stage kidney disease, treatment options have been limited and have serious side effects,” said the ICER’s chief medical officer Dr David Rind, adding: “New non-glucocorticoid therapies targeted at B-cells appear likely to provide greater efficacy with fewer side effects, although longer term data are needed. Despite this, the very high price for sibeprenlimab led the independent appraisal council to conclude that it provides low value for money. We hope that the price of atacicept aligns better with the benefits it provides.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze